On November 15, 2022, Health Canada released a new guidance document, “Guidance on clinical evidence requirements for medical devices.” In this document, Health Canada provides guidance on clinical evidence requirements for Class II, III, and IV medical devices. This document does not apply to in vitro diagnostic devices (IVDDs).
The document includes guidance on when clinical data/evidence is required, methods to generate and evaluate clinical data, and how to compare devices appropriately. It also provides general principles and criteria for clinical evidence that supports amending licence applications, and additional obligations during the post-market phase.
Health Canada also released a companion document, “Examples of clinical evidence requirements for medical devices,” which contains examples of different types of devices and outlines when clinical evidence is more likely or less likely to be required.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More